Proposed mechanisms of Tesamorelin: Activates GHRH receptors Increases endogenous GH release Elevates IGF-1 production Promotes lipolysis Reduces visceral adipose tissue Why Tesamorelin is unique: Unlike most weight-loss therapies, Tesamorelin appears particularly effective at reducing visceral fat the deep abdominal fat surrounding internal organs that is strongly associated with insulin resistance, cardiovascular disease, and metabolic syndrome
The Shared Foundation: GHK-Cu + BPC-157 + TB-500 Both GLOW and KLOW are built on the same three-peptide base a combination that pairs the leading compounds from skin/anti-aging research and recovery research: This three-way base is studied for combining the major tissue-repair mechanisms gene expression (GHK-Cu), angiogenesis (BPC-157), and cell migration (TB-500) in a single formulation
Dosing structure below is community-derived from individual-compound research
Because the compound lacks regulatory approval, any product marketed for human use is being sold through unofficial channels that do not meet pharmaceutical manufacturing standards, raising documented concerns about purity, composition, and contamination